The colorectal cancer screening market is heating up in 2022, with three large pivotal trials expected to be made public this year, as liquid biopsies in development at Freenome and Guardant Health pose a potential competitive challenge to Exact Sciences’ market-leading Cologuard stool DNA test.
Guardant Health CEO Helmy Eltoukhy told MedTech Dive the precision oncology company plans to launch a liquid biopsy for colorectal cancer screening in the first half of the year, called Guardant Shield, and which is meant to challenge Exact Sciences’ Cologuard as well as invasive colonoscopies.